Primärdiagnostik, Therapieansprechen und Rezidivdiagnostik maligner Lymphome

[1]  H. Amthauer,et al.  Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. , 2008, Blood.

[2]  H. Eich,et al.  Involved-Node Radiotherapy in Early-Stage Hodgkin’s Lymphoma , 2008, Strahlentherapie und Onkologie.

[3]  H. Eich,et al.  Current Role and Future Developments of Radiotherapy in Early-stage Favourable Hodgkin's Lymphoma , 2007, Strahlentherapie und Onkologie.

[4]  H. Eich,et al.  A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). , 2007, International journal of radiation oncology, biology, physics.

[5]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Specht,et al.  Clinical impact of FDG‐PET/CT in the planning of radiotherapy for early‐stage Hodgkin lymphoma , 2007, European journal of haematology.

[7]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Noordijk,et al.  Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  M. Dietlein,et al.  Diagnostik des Hodgkin-Lymphoms — state of the art , 2005, Der Onkologe.

[10]  H. Eich,et al.  CT and MR imaging in Hodgkin's disease – present and future , 2005, European journal of haematology. Supplementum.

[11]  J. Debatin,et al.  Whole-body MR imaging: evaluation of patients for metastases. , 2004, Radiology.

[12]  H. Eich,et al.  Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group. , 2004, International journal of radiation oncology, biology, physics.

[13]  P. Babyn,et al.  Fast STIR whole-body MR imaging in children. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[14]  H. Eich,et al.  Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. , 2004, International journal of radiation oncology, biology, physics.

[15]  P. Dupont,et al.  Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? , 2001, British journal of haematology.

[16]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Castellino.  Diagnostic imaging studies in patients with newly diagnosed Hodgkin's disease. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  E. Fishman,et al.  CT of lymphoma: spectrum of disease. , 1991, Radiographics : a review publication of the Radiological Society of North America, Inc.

[19]  V. Diehl,et al.  Malignant lymphoma: bone marrow imaging versus biopsy. , 1989, Radiology.

[20]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. C. Campbell,et al.  The immunohistology of Hodgkin's disease—Reed–Sternberg cells and their variants , 1987, The Journal of pathology.

[22]  R. Castellino,et al.  Hodgkin disease: contributions of chest CT in the initial staging evaluation. , 1986, Radiology.

[23]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[24]  M. Juweid.  Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. , 2006, Hematology. American Society of Hematology. Education Program.

[25]  R. Hustinx,et al.  Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  L. Bonomo,et al.  Staging of thoracic lymphoma by radiological imaging , 1997, European Radiology.

[27]  H. Sandler,et al.  Analysis of localization errors in the definition of the mantle field using a beam's eye view treatment-planning system. , 1996, International journal of radiation oncology, biology, physics.